APA (7th ed.) Citation

H, S., XY, L., XY, J., WQ, J., HR, X., JK, H., . . . Y, X. (2026). Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapy. Acta pharmacologica Sinica. https://doi.org/10.1038/s41401-026-01856-z

Chicago Style (17th ed.) Citation

H, Shen, et al. "Development of XYD113 as a Potent and Highly Selective GSPT1 Degrader for Cancer Therapy." Acta Pharmacologica Sinica 2026. https://doi.org/10.1038/s41401-026-01856-z.

MLA (9th ed.) Citation

H, Shen, et al. "Development of XYD113 as a Potent and Highly Selective GSPT1 Degrader for Cancer Therapy." Acta Pharmacologica Sinica, 2026, https://doi.org/10.1038/s41401-026-01856-z.